The consolidation brings together two organizations with a history of robust growth and performance ready to build on this strength using the outstanding talent of both companies to deliver enhanced ...

ICON has agreed to acquire PRA Health Sciences for approximately $12 billion in cash and stock, the companies said, in a deal that continues the consolidation of contract research organizations (CROs) ...

The PRA acquisition deal is a combination of cash and stock. According to terms announced Wednesday, PRA shareholders will receive $80 cash for each share of PRA that they own, plus 0.4125 shares in ...

Shares of PRA Health Sciences jumped nearly 18.7% on Feb. 24 after the research company inked a deal with ICON plc to be acquired in a cash-and-stock deal worth $12 billion. Per the terms of the ...

Icon had a tough 12 months but is bouncing back in 2021 with returns to growth, new collabs and, oh, that $12 billion deal to snap up a rival company. For its fourth-quarter and full-year financials, ...

Clinical-trial operator Icon PLCICLR0.48%increase; green up pointing triangle said it would acquire rival PRA Health Sciences Inc. for $12 billion, creating a powerhouse provider of services to ...

Icon PLC, a provider of outsourced drug and device development to the drug and medical device industries, said Wednesday it has agreed to acquire PRA Health Sciences Inc. in a cash and stock deal ...

Icon Plc agreed to buy PRA Health Sciences Inc. in a $12 billion cash and stock deal that combines two research providers supporting Covid vaccine and treatment trials. Both companies help run ...